ArriVent BioPharma, Inc.

General Information

We are a Phase 3 clinical biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. (Incorporated in Delaware)

We seek to utilize our team’s deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is currently being evaluated in multiple clinical trials across a range of epidermal growth factor receptor (EGFR) mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a pivotal Phase 3 clinical trial in treatment naive, or first-line, patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations. We received Breakthrough Therapy Designation for furmonertinib for the treatment of this disease from the U.S. Food and Drug Administration (FDA) in October 2023. A product candidate can receive Breakthrough Therapy Designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for development. The receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and does not increase the likelihood that the product candidate will ultimately receive FDA approval for any indication.

Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor (TKI) that we are developing for the treatment of NSCLC patients across a broader set of EGFR mutations (EGFRm) than are currently served by approved EGFR TKIs. Furmonertinib is currently only approved and commercially distributed by Shanghai Allist Pharmaceuticals Company, Ltd. (Allist) in China as a first-line therapy to treat classical EGFRm NSCLC. The FDA has not approved furmonertinib for any use. We selected furmonertinib for global development against nonclassical, or uncommon, mutations based on preliminary reductions in tumor size observed in seven out of 10 patients in first-line treatment with EGFR exon 20 insertion mutations in the ongoing Phase 1b clinical trial, the FAVOUR trial, conducted by Allist in China, and preclinical activity in P-loop and-alpha-c-helix compressing (PACC) mutations, each a subtype of uncommon mutation. In a subsequent interim data readout from the FAVOUR trial of furmonertinib in first-line patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, 79% of patients (n=22 out of 28 patients) were observed to experience a reduction in tumor size of at least 30%. Allist expects to release final results of the primary analysis from the FAVOUR study in 2024. If the future clinical trial results of the FAVOUR trial are unfavorable, our clinical development plans for furmonertinib, which include conducting our global pivotal Phase 3 FURVENT clinical trial in first-line non-squamous locally advanced or metastatic EGFRm NSCLC patients with exon 20 insertion mutations, may be adversely affected. In 2021, we licensed from Allist the right to develop and commercialize furmonertinib worldwide, with the exception of greater China, which includes mainland China, Hong Kong, Macau and Taiwan.

Note: Net loss and revenue figures are for the 12 months that ended Sept. 30, 2023.

(Note: ArriVent BioPharma, Inc. upsized its IPO at pricing to 9.72 million shares (9,722,222 shares) – up from 8.33 million shares in the prospectus – and priced the IPO at $18.00 – the mid-point of its $17.00-to-$19.00 range – to raise $175 million on Thursday night, Jan. 25, 2024, according to the company’s pricing announcement. The stock is expected to start trading under the proposed symbol “AVBP” on Friday, Jan. 26, 2024, on the NASDAQ.)

(Note: ArriVent BioPharma, Inc., filed its S-1/A on Jan. 22, 2024, and disclosed terms for its IPO: 8.33 million shares (8,333,333 shares) at a price range of $17.00 to $19.00 to raise $149.94 million. Background: ArriVent BioPharma, Inc., filed its S-1 on Jan. 5, 2024, without disclosing the terms for its IPO.)

Industry: Pharmaceuticals
Employees: 40
Founded: 2021
Contact Information
Address 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073
Phone Number (628) 277-4836
Web Address
View Prospectus: ArriVent BioPharma, Inc.
Financial Information
Market Cap $575.24mil
Revenues $0 mil (last 12 months)
Net Income $-58.58 mil (last 12 months)
IPO Profile
Symbol AVBP
Exchange NASDAQ
Shares (millions): 9.7
Price range $18.00 - $18.00
Est. $ Volume $175.0 mil
Manager / Joint Managers Goldman Sachs/ Jefferies/ Citigroup/ LifeSci Capital
Expected To Trade: 1/26/2024
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change